You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞科生物-B(02179.HK):與印度Biological E公司就重組九價HPV疫苗REC603達成產品授權合作

格隆匯6月30日丨瑞科生物-B(02179.HK)發佈公告,公司與印度知名生物製品公司Biological E(“BE公司”)近日就重組九價HPV疫苗REC603簽署產品授權合作協議(“協議”)。公司將向BE公司進行疫苗配製及分包裝技術授權,並在適當時機進行原液生產技術授權。根據協議,BE公司被獨家授權在印度以及由聯合國兒童基金會(UNICEF)、泛美衛生組織(PAHO)主導的招標市場進行重組九價HPV疫苗的開發,生產及商業化。目前,公司已收到合作預付款,並將按照合作進度收取里程碑付款,以及基於一定比例年淨銷售額的特許權使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account